newsfilter
← Latest News
Business Wire·

Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update

Revenue of $256.1 million, a 32 percent increase over the same period in 2025 Korlym® and authorized generic product revenue of $208.6 million Lifyorli™ product revenue of $47.6 million Increase in 2026